Description

Setmelanotide is a potent cyclic peptide analog of ?-melanocyte stimulating hormone (?-MSH) and selectively activates MC4R in the hypothalamus to suppress appetite and increase energy expenditure. It is the first approved pharmacological agent for obesity driven by rare genetic deficiencies in POMC, PCSK1, LEPR, or Bardet-Biedl syndrome. Engineered for high specificity, Setmelanotide avoids cardiovascular side effects typical of earlier MC4R agonists. With GMP-grade manufacturing and ?99.93% purity, it’s a reliable tool for advanced metabolic and genetic obesity research.

Product Specifications

Mechanism of Action & Research Applications

Setmelanotide binds MC4R in the hypothalamus, enhancing cAMP signaling to suppress hunger and boost energy use. It’s used in research on:

• Genetic obesity due to POMC, PCSK1, or LEPR deficiencies

• Bardet-Biedl syndrome obesity models

• Appetite regulation and metabolic thermogenesis studies

• Energy expenditure and weight control mechanisms

Unlike earlier MC4R agonists, Setmelanotide does not raise heart rate or blood pressure in tested models.

Side Effects (For Research Context Only)

Commonly observed in clinical and experimental contexts:

• Injection site reactions

• Skin hyperpigmentation or darkening of existing nevi

• Gastrointestinal symptoms: nausea, vomiting, abdominal discomfort

• Headache and fatigue

• Rare behavioral effects: spontaneous erections, mood changes

• Mild hypotensive effects have been reported under specific conditions

These findings help guide dosage and monitoring strategies in preclinical research.

Disclaimer

Setmelanotide is strictly for laboratory research use only. Not approved for clinical, diagnostic, or therapeutic use.